Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves' diseases: a case-control study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan
      Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan
      Department of Ophthalmology, Taipei City Hospital, Zhongxing Branch, Taipei, Taiwan
      Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, No. 1, Section 1, Ren-Ai Road, 10051, Taipei, Taiwan
      Ansn Clinic, Hsin-Chu, Taiwan
      Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
      Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
      Center of Anti-Aging and Health Consultation, National Taiwan University Hospital, Taipei, Taiwan
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      Summary: This study investigated the alterations of mineral metabolism in patients with Graves' disease (GD) who achieved euthyroidism. They had higher fibroblast growth factor 23 (FGF23) and phosphorus as compared with healthy subjects. Serum FGF23 was negatively correlated with serum phosphorus. These indicated abnormal mineral metabolism even after 1.6 years of euthyroid status. Introduction: FGF23 is involved in the mineral homeostasis, especially the regulation of serum phosphorus. Graves' disease (GD) is associated with accelerated bone turnover, hyperphosphatemia, and elevated serum FGF23. Evidence suggested that serum FGF23 decreased after a 3-month treatment of GD. However, it remains unclear whether serum FGF23, serum phosphorus, and other markers of mineral metabolism will be normalized after euthyroid status achieved. Methods: A total of 62 patients with euthyroid GD and 62 healthy control subjects were enrolled, and the median duration of euthyroid status was 1.6 years. Endocrine profiles including thyroid function test, autoantibodies, serum FGF23, and bone turnover markers were obtained and compared between the two groups. Results: Euthyroid GD patients had significantly higher serum FGF23 and phosphorus, and lower 25-hydroxyvitamin D (25(OH)D) and intact parathyroid hormone (iPTH) levels as compared with the control group. Serum FGF23 was significantly and negatively correlated with phosphorus level after adjusted for age, gender, calcium, iPTH, and 25(OH)D in the euthyroid GD group. Conclusion: Serum phosphorus and FGF23 levels remain higher in GD patients even after euthyroid status has been achieved for a median of 1.6 years. Serum FGF23 was negatively correlated with serum phosphorus in euthyroid GD patients. Underlying mechanisms warrant further investigations. Trial registration: Registration number: NCT01660308 and NCT02620085
    • Journal Subset:
      Biomedical; Europe; Peer Reviewed; UK & Ireland
    • ISSN:
      0937-941X
    • MEDLINE Info:
      NLM UID: 9100105
    • Publication Date:
      20191102
    • Publication Date:
      20200305
    • DOI:
      http://dx.doi.org/10.1007/s00198-019-05116-1
    • Accession Number:
      139275795
  • Citations
    • ABNT:
      LIN, C.-H. et al. Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study. Osteoporosis International, [s. l.], v. 30, n. 11, p. 2289–2297, 2019. DOI 10.1007/s00198-019-05116-1. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=139275795. Acesso em: 22 set. 2020.
    • AMA:
      Lin C-H, Chang C-K, Shih C-W, et al. Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study. Osteoporosis International. 2019;30(11):2289-2297. doi:10.1007/s00198-019-05116-1
    • APA:
      Lin, C.-H., Chang, C.-K., Shih, C.-W., Li, H.-Y., Chen, K.-Y., Yang, W.-S., Tsai, K.-S., Wang, C.-Y., & Shih, S.-R. (2019). Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study. Osteoporosis International, 30(11), 2289–2297. https://doi.org/10.1007/s00198-019-05116-1
    • Chicago/Turabian: Author-Date:
      Lin, C.-H., C.-K. Chang, C.-W. Shih, H.-Y. Li, K.-Y. Chen, W.-S. Yang, K.-S. Tsai, C.-Y. Wang, and S.-R. Shih. 2019. “Serum Fibroblast Growth Factor 23 and Mineral Metabolism in Patients with Euthyroid Graves’ Diseases: A Case-Control Study.” Osteoporosis International 30 (11): 2289–97. doi:10.1007/s00198-019-05116-1.
    • Harvard:
      Lin, C.-H. et al. (2019) ‘Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study’, Osteoporosis International, 30(11), pp. 2289–2297. doi: 10.1007/s00198-019-05116-1.
    • Harvard: Australian:
      Lin, C-H, Chang, C-K, Shih, C-W, Li, H-Y, Chen, K-Y, Yang, W-S, Tsai, K-S, Wang, C-Y & Shih, S-R 2019, ‘Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study’, Osteoporosis International, vol. 30, no. 11, pp. 2289–2297, viewed 22 September 2020, .
    • MLA:
      Lin, C. H., et al. “Serum Fibroblast Growth Factor 23 and Mineral Metabolism in Patients with Euthyroid Graves’ Diseases: A Case-Control Study.” Osteoporosis International, vol. 30, no. 11, Nov. 2019, pp. 2289–2297. EBSCOhost, doi:10.1007/s00198-019-05116-1.
    • Chicago/Turabian: Humanities:
      Lin, C.-H., C.-K. Chang, C.-W. Shih, H.-Y. Li, K.-Y. Chen, W.-S. Yang, K.-S. Tsai, C.-Y. Wang, and S.-R. Shih. “Serum Fibroblast Growth Factor 23 and Mineral Metabolism in Patients with Euthyroid Graves’ Diseases: A Case-Control Study.” Osteoporosis International 30, no. 11 (November 2019): 2289–97. doi:10.1007/s00198-019-05116-1.
    • Vancouver/ICMJE:
      Lin C-H, Chang C-K, Shih C-W, Li H-Y, Chen K-Y, Yang W-S, et al. Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study. Osteoporosis International [Internet]. 2019 Nov [cited 2020 Sep 22];30(11):2289–97. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=139275795